Table 1 Demographic characteristics of patients with device-associated osteomyelitis treated with daptomycin in the CORE database
From: A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin
Characteristic | No follow-up in CORE 2009 | Evaluable population | |
|---|---|---|---|
PJI | OHAO | ||
(n = 32) | (n = 27)a | (n = 21)a | |
Sex, n (%) | |||
Female | 18 (56.3) | 12 (44.4) | 12 (57.1) |
Male | 14 (43.8) | 15 (55.6) | 9 (42.9) |
Median weight, kg (range) | 81.4 (37.1–120.0) | 86.4 (44.1–128.9) | 79.0 (40.0–136.4) |
Age group (y), n (%) | |||
≤ 50 | 6 (18.8) | 4 (14.8) | 13 (61.9) |
51–65 | 14 (43.8) | 12 (44.4) | 7 (33.3) |
≥ 66 | 12 (37.5) | 11 (40.7) | 1 (4.8) |
In community 48 h prior to receiving daptomycin, n (%) | 15 (46.9) | 13 (48.1) | 11 (52.4) |
ICU stay during daptomycin, n (%) | 7 (21.9) | 1 (3.7) | 0 (0.0) |
Initial creatinine clearance | 5 (15.6) | 2 (7.4) | 0 (0.0) |
< 30 mL/min, n (%) | |||
Surgical intervention, n (%) | 22 (68.8) | 22 (81.5) | 17 (81.0) |
At least 1 pathogen identified, n (%) | 22 (68.8) | 20 (74.1) | 18 (85.7) |
Median initial daptomycin dose, mg/kg (range) | 6 (4–13.5) | 6 (4–9) | 6 (4–8) |
Median duration of daptomycin, days (range) | 35 (2–78) | 41 (6–70) | 40 (8–62) |